Metformin 500 mg
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest metformin 500 mg is effective for lowering blood glucose in type II diabetes, well-tolerated, and bioequivalent across different formulations, while also showing potential benefits for PCOS and mild cognitive impairment, but not significantly affecting birthweight in obese pregnant women or polyp reduction in FAP patients.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Efficacy and Safety of Metformin 500 mg: A Comprehensive Review
Introduction to Metformin 500 mg
Metformin is a widely used medication for managing type II diabetes mellitus. It is known for its efficacy in lowering blood glucose levels and improving insulin sensitivity. This article synthesizes research findings on the efficacy, safety, and various applications of metformin 500 mg.
Efficacy in Type II Diabetes Management
Blood Glucose and HbA1c Reduction
Metformin 500 mg has been shown to significantly improve glucose variables in patients with type II diabetes. In a 14-week, multicenter, double-blind study, metformin at 500 mg daily reduced fasting plasma glucose and glycated hemoglobin (HbA1c) levels compared to placebo. The adjusted mean changes in fasting plasma glucose from baseline exceeded those associated with placebo by 19 to 84 mg/dL, and the differences in HbA1c ranged from 0.6% to 2.0% at dosages of 500 to 2000 mg daily.
Bioequivalence and Pharmacokinetics
Studies comparing different brands of metformin 500 mg tablets, such as Dialon® and Glucophage®, have demonstrated bioequivalence. Pharmacokinetic parameters including AUC and Cmax were within the bioequivalence acceptance range of 80-125%, indicating that different formulations of metformin 500 mg are similarly effective .
Safety and Tolerability
Adverse Events
Metformin is generally well-tolerated, but treatment-related adverse events, primarily digestive disturbances like diarrhea, have been reported. In a study, 28% of patients on metformin experienced adverse events compared to 15% in the placebo group. Another study found that 7.5% of participants could not tolerate metformin due to gastrointestinal symptoms.
Use in Patients with Reduced Kidney Function
For patients with reduced kidney function, a lower dose of 500 mg daily is recommended to maintain plasma metformin concentrations below safety limits. This dosing strategy helps minimize the risk of lactic acidosis while ensuring efficacy.
Applications Beyond Diabetes
Cognitive Impairment
Metformin has been explored for its potential benefits in cognitive impairment. A pilot study involving participants with amnestic mild cognitive impairment (aMCI) found that metformin 500 mg daily was generally well-tolerated and showed some promise in improving cognitive outcomes, although larger trials are needed to confirm these findings.
Polycystic Ovary Syndrome (PCOS)
In women with PCOS who are resistant to clomiphene citrate (CC), metformin 500 mg three times daily significantly increased ovulation and pregnancy rates when combined with CC treatment. This suggests that metformin can enhance fertility outcomes in this population.
Pregnancy Outcomes in Obese Women
A study on obese pregnant women without diabetes found that metformin 500 mg daily did not significantly affect birthweight percentiles. Therefore, metformin should not be used to improve pregnancy outcomes in obese women without diabetes.
Familial Adenomatous Polyposis (FAP)
A trial investigating the effect of metformin on adenomas in patients with FAP found no significant reduction in the number or size of polyps with 500 mg or 1500 mg daily doses. Thus, metformin is not recommended for promoting regression of intestinal adenomas in FAP patients.
Conclusion
Metformin 500 mg is effective in managing blood glucose levels in type II diabetes and is generally well-tolerated. It has potential applications in cognitive impairment and PCOS but shows limited efficacy in improving pregnancy outcomes in obese women without diabetes and in treating adenomas in FAP patients. Proper dosing, especially in patients with reduced kidney function, is crucial to ensure safety and efficacy.
Sources and full results
Most relevant research papers on this topic
